{"id":621569,"date":"2022-10-18T16:10:01","date_gmt":"2022-10-18T16:10:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=621569"},"modified":"2022-10-18T16:10:01","modified_gmt":"2022-10-18T16:10:01","slug":"venous-thromboembolism-pipeline-assessment-clinical-trials-fda-ema-and-pmda-approvals-emerging-drugs-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/venous-thromboembolism-pipeline-assessment-clinical-trials-fda-ema-and-pmda-approvals-emerging-drugs-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight_621569.html","title":{"rendered":"Venous Thromboembolism Pipeline Assessment &#8211; Clinical Trials, FDA, EMA, and PMDA Approvals, Emerging Drugs, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1666065554.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Venous Thromboembolism Pipeline Assessment - Clinical Trials, FDA, EMA, and PMDA Approvals, Emerging Drugs, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1666065554.jpeg\" alt=\"Venous Thromboembolism Pipeline Assessment - Clinical Trials, FDA, EMA, and PMDA Approvals, Emerging Drugs, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Venous Thromboembolism Pipeline<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Venous thromboembolism pipeline constitutes 10+ key companies continuously working towards developing 10+ Venous thromboembolism treatment therapies, analyzes DelveInsight<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">Venous thromboembolism (VTE) is a disease that includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). It is a common, lethal disorder that affects both hospitalized and nonhospitalized patients. PE and DVT are 2 clinical presentations of VTE and share the same predisposing factors. In most cases, PE is a consequence of DVT.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>&ldquo;Venous Thromboembolism Pipeline Insight, 2022&rdquo;<\/strong> report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Venous Thromboembolism Market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Venous Thromboembolism Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/www.abnewswire.com\/uploads\/5f9086cad5275c2db7303f1ffe34b2f9.jpg\" alt=\"\" \/><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for sample and discover more about the Venous Thromboembolism report offerings @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/venous-thromboembolism-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Venous Thromboembolism Pipeline Insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>DelveInsight&rsquo;s Venous Thromboembolism Report covers around 10+ products under different phases of clinical development like<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; Late-stage Venous Thromboembolism products (Phase III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; Mid-stage Venous Thromboembolism products (Phase II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; Early-stage Venous Thromboembolism product (Phase I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; Pre-clinical and Discovery stage candidates<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; Discontinued &amp; Inactive candidates<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; Venous Thromboembolism Route of Administration<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Emerging Venous Thromboembolism Drugs Under Different Phases of Clinical Development Include:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; Isoquercetin: Quercis Pharma<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; Abelacimab: Anthos therapeutics<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;&nbsp;And Many Others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Further Venous Thromboembolism product details are provided in the report. Download the Venous Thromboembolism pipeline report to learn more about the emerging Venous Thromboembolism therapies at:&nbsp;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/venous-thromboembolism-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/venous-thromboembolism-pipeline-insight<\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Venous Thromboembolism Pipeline Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Venous Thromboembolism report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the treatment of Venous Thromboembolism with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Venous Thromboembolism Treatment.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Venous Thromboembolism key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Venous Thromboembolism Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Venous Thromboembolism market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Find a snapshot of the Venous Thromboembolism Treatment landscape @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/venous-thromboembolism-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"> Venous Thromboembolism Therapies and drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key companies in the Venous Thromboembolism Therapeutics Market include:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Some of the Venous Thromboembolism Companies working in the market are Quercis Pharma, Tetherex Pharmaceuticals, Ono Pharmaceutical, Anthos therapeutics, Bristol Myers Squibb, Yuhan Corporation, Supergene, Tasly Pharmaceutical, GlycoMimetics and Others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn more about Venous Thromboembolism Drugs Pipeline @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/venous-thromboembolism-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"> Venous Thromboembolism clinical trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Venous Thromboembolism Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Venous Thromboembolism &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Venous Thromboembolism Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Venous Thromboembolism Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Venous Thromboembolism Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Venous Thromboembolism Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9.&nbsp; Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Venous Thromboembolism Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Venous Thromboembolism Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Venous Thromboembolism Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Venous Thromboembolism Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Key Companies in the Venous Thromboembolism Market<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Key Products in the Venous Thromboembolism Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Venous Thromboembolism Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Venous Thromboembolism Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Venous Thromboembolism Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get in touch with our Business Consultant to get detailed insights into &ndash; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/venous-thromboembolism-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Venous Thromboembolism Pipeline Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=venous-thromboembolism-pipeline-assessment-clinical-trials-fda-ema-and-pmda-approvals-emerging-drugs-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/venous-thromboembolism-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/venous-thromboembolism-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/venous-thromboembolism-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=venous-thromboembolism-pipeline-assessment-clinical-trials-fda-ema-and-pmda-approvals-emerging-drugs-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Venous Thromboembolism Pipeline Venous thromboembolism pipeline constitutes 10+ key companies continuously working towards developing 10+ Venous thromboembolism treatment therapies, analyzes DelveInsight Venous thromboembolism (VTE) is a disease that includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). It is &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/venous-thromboembolism-pipeline-assessment-clinical-trials-fda-ema-and-pmda-approvals-emerging-drugs-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight_621569.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,423,404],"tags":[],"class_list":["post-621569","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Professional-Services","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/621569","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=621569"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/621569\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=621569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=621569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=621569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}